Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Sets New 12-Month Low – Time to Sell?

Shares of Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) reached a new 52-week low on Monday . The company traded as low as $52.25 and last traded at $52.25, with a volume of 0 shares trading hands. The stock had previously closed at $52.25.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Stock Performance

The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.95 and a current ratio of 1.36. The company has a market cap of $10.78 billion, a P/E ratio of 26.13 and a beta of 0.33. The stock has a 50-day moving average of $52.25 and a two-hundred day moving average of $51.84.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.70 earnings per share for the quarter. Recordati Industria Chimica e Farmaceutica had a return on equity of 30.78% and a net margin of 17.41%. The company had revenue of $622.00 million during the quarter.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.